Vaxcyte (PCVX) Other Accumulated Expenses (2019 - 2023)

Vaxcyte (PCVX) has reported Other Accumulated Expenses for 5 consecutive years, with $1.9 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Other Accumulated Expenses rose 34.66% year-over-year to $1.9 million; the TTM figure through Dec 2023 stood at $1.9 million (up 34.66% YoY), while the FY2023 annual figure was $1.9 million, up 34.66% from the prior year.
• Other Accumulated Expenses fell to $1.9 million in Q4 2023 per PCVX's latest filing, from $2.5 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $5.0 million in Q3 2021 and bottomed at $64000.0 in Q4 2019.
• Historically, Other Accumulated Expenses has averaged $1.8 million across 5 years, with a median of $1.5 million in 2022.
• Annual changes were most pronounced in 2021 — Other Accumulated Expenses jumped 1267.24% — and 2022, when it sank 76.67%.
• Vaxcyte's Other Accumulated Expenses stood at $64000.0 in 2019, then jumped by 575.0% to $432000.0 in 2020, then jumped by 746.76% to $3.7 million in 2021, then sank by 61.43% to $1.4 million in 2022, then jumped by 34.66% to $1.9 million in 2023.
• Business Quant data shows PCVX's Other Accumulated Expenses at $1.9 million in Q4 2023, $2.5 million in Q3 2023, and $1.9 million in Q2 2023.